MeSH term
Frequency | Condition_Probility | Animals | 8 | 0.0 |
Humans | 44 | 0.0 |
Research Support, Non-U.S. Gov't | 22 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 6 | 0.0 |
Blotting, Northern | 2 | 0.0 |
Blotting, Western | 2 | 0.0 |
Cell Line | 4 | 0.0 |
DNA Mutational Analysis | 3 | 0.0 |
Green Fluorescent Proteins | 2 | 0.0 |
*Mutation | 3 | 0.0 |
Phenotype | 5 | 0.0 |
Rats | 2 | 0.0 |
Temperature | 2 | 0.0 |
Aged | 6 | 0.0 |
Female | 21 | 0.0 |
Male | 23 | 0.0 |
Middle Aged | 14 | 0.0 |
Prospective Studies | 2 | 0.0 |
Adult | 14 | 0.0 |
English Abstract | 11 | 0.0 |
Alleles | 2 | 0.0 |
Pedigree | 2 | 0.0 |
Base Sequence | 4 | 0.0 |
Molecular Sequence Data | 6 | 0.0 |
Cell Cycle Proteins/metabolism | 2 | 0.0 |
Child | 8 | 0.0 |
Phenylketonurias/*genetics/metabolism | 2 | 100.0 |
Amino Acid Sequence | 3 | 0.0 |
Liver Function Tests | 2 | 1.0 |
Prevalence | 2 | 0.0 |
Retrospective Studies | 3 | 0.0 |
In Vitro | 3 | 0.0 |
Mice | 3 | 0.0 |
Swine | 2 | 0.0 |
Adolescent | 6 | 0.0 |
Child, Preschool | 6 | 0.0 |
Chromatography, High Pressure Liquid | 2 | 0.0 |
Cells, Cultured | 2 | 0.0 |
Case-Control Studies | 2 | 0.0 |
Follow-Up Studies | 2 | 0.0 |
Time Factors | 2 | 0.0 |
Comparative Study | 7 | 0.0 |
Phosphoenolpyruvate Sugar Phosphotransferase System/metabolism | 2 | 66.0 |
Dose-Response Relationship, Drug | 2 | 0.0 |
Infant | 5 | 0.0 |
*Prothrombin Time | 2 | 10.0 |
Cardiomyopathy, Dilated/*physiopathology | 2 | 28.0 |
Prothrombin Time | 2 | 1.0 |
Heterozygote | 2 | 0.0 |
Phenylalanine/*blood | 2 | 9.0 |
*Phosphorus-Oxygen Lyases | 2 | 100.0 |
